Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.